Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure (ESCAPE-SHF)

ESCAPE-SHF: A Double-blind, Double-dummy, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Systolic Heart Failure

In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level. An increase of angiotensin II is associated with progression of heart failure. Although the use of ACE-inhibitors in heart failure shows clinical benefit, an increase in angiotensin II due to an angiotensin II "escape" phenomenon is not desirable. It is not yet known if a direct renin inhibitor can reduce or even prevent the angiotensin II escape phenomenon associated with the use of an ACE-inhibitor. Therefore the study tested the effects of ramipril, aliskiren and the combination of both on levels of angiotensin II in the blood in patients with systolic heart failure

Study Overview

• Status: Completed
• Conditions: Heart Failure
• Intervention / Treatment: Drug: aliskiren; Drug: ramipril; Drug: Placebo to ramipril; Drug: Placebo to aliskiren

• Study Type: Interventional
• Enrollment (Actual): 123
• Phase: Phase 2

Contacts and Locations

Study Locations

• Germany
  • Bad Krozingen, Germany, 79189
    • Novartis Investigator Site
  • Berlin, Germany, 12207
    • Novartis Investigator Site
  • Berlin, Germany, 13353
    • Novartis Investigator Site
  • Göttingen, Germany, 37057
    • Novartis Investigator Site
  • Jena, Germany, 07747
    • Novartis Investigator Site
  • München, Germany, 80336
    • Novartis Investigator Site
• Poland
  • Krakow, Poland, 31-501
    • Novartis Investigator Site
  • Lublin, Poland, 20-090
    • Novartis Investigator Site
  • Poznan, Poland, 61-848
    • Novartis Investigator Site
  • Warszawa, Poland, 02-507
    • Novartis Investigator Site
  • Wroclaw, Poland, 50-981
    • Novartis Investigator Site
• Russian Federation
  • Moscow, Russian Federation
    • Novartis Investigative Site
  • Moscow, Russian Federation, 117292
    • Novartis Investigator Site
  • Moscow, Russian Federation, 119620
    • Novartis Investigator Site
  • Moscow, Russian Federation, 121309
    • Novartis Investigator Site
  • Moscow, Russian Federation, 121552
    • Novartis Investigator Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Decompensated systolic heart failure, left ventricular ejection fraction ≤40%
• Brain natriuretic peptide (BNP) level ≥ 100 pg/mL

Exclusion criteria:

• Use of Angiotensin Converting Enzyme(ACE) or Angiotensin Receptor Blocker (ARB) inhibitor treatment following the run-in period or requirement of both treatments
• Acute heart failure secondary to acute myocardial infarction, acute coronary syndrome or new tachyarrhythmia
• Occurrence of unstable angina or myocardial infarction within 12 weeks prior to screening
• History of cardiomyopathy such as postpartum, restrictive, infective, hypertrophic obstructive
• History of right heart failure due to pulmonary disease
• History of untreated second or third degree atrioventricular heart block

Other protocol-defined inclusion/exclusion criteria applied

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Aliskiren; In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.	Drug: aliskiren; Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site; Drug: ramipril; 2.5 mg , 5.0 mg or 10 mg once daily; Drug: Placebo to ramipril; Matching placebo to ramipril capsule in double blind phase
EXPERIMENTAL: Ramipril; In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet.	Drug: ramipril; 2.5 mg , 5.0 mg or 10 mg once daily; Drug: Placebo to aliskiren; matching placebo to aliskiren in double blind phase
EXPERIMENTAL: Aliskiren plus Ramipril; In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site	Drug: aliskiren; Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site; Drug: ramipril; 2.5 mg , 5.0 mg or 10 mg once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Venous Angiotensin II Levels After 12 Weeks of Treatment	Peripheral venous blood was collected after 30 minutes of rest in the sitting position for analysis of biomarkers. Geometric mean ratio to baseline at Week 12 for Venous angiotensin II levels was calculated in patients with decompensated systolic heart failure (SHF) and left ventricular ejection fraction ≤40% at 0 hour pre-dose, 3 hours and 24 hours post-dose.	Baseline. 12 Weeks (Day 84, period 2)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biomarker Plasma Renin Concentration (PRC)After 12 Weeks of Treatment	Peripheral venous blood was collected after 30 minutes of rest in the sitting position for analysis of biomarkers. Geometric Mean Ratio to baseline at 12 weeks for PRC was calculated at 0 hour pre-dose.	Baseline, 12 weeks (84 days, period 2)
Biomarker Trapping Plasma Renin Activity (tPRA) After 12 Weeks of Treatment	Peripheral venous blood was collected after 30 minutes of rest in the sitting position for analysis of biomarkers. Geometric Mean Ratio to baseline at Week 12 for tPRA was calculated at 0 hour pre-dose, 3 hour and 24 hour post-dose.	Baseline,12 weeks (84 days, Period 2)
Biomarker B-type Natriuretic Peptide (BNP) After 12 Weeks of Treatment	Peripheral venous blood was collected after 30 minutes of rest in the sitting position for analysis of biomarkers. Geometric Mean Ratio to baseline at Week 12 for BNP was calculated at 0 hours pre-dose.	Baseline, 12 weeks (Day 84 period 2)
Biomarker Urinary Aldosterone After 12 Weeks of Treatment	24 hour urine collections were performed. Geometric Mean Ratio to baseline at Week 12 for Urinary aldosterone was calculated 24 hours post-dose.	Baseline,12 weeks (Day 84 period 2)
Pharmacokinetic of Aliskiren: Time to Reach the Maximum Concentration (Tmax) After Drug Administration	Blood samples (2 mL) for the determination of aliskiren concentration in plasma were collected using an indwelling cannula inserted in a forearm vein. Samples were collected at week 12 (day 84): pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose.	12 weeks
Pharmacokinetic of Aliskiren: The Observed Maximum Plasma Concentration (Cmax) Following Drug Administration	Blood samples (2 mL) for the determination of aliskiren concentration in plasma were collected using an indwelling cannula inserted in a forearm vein. Samples were collected at week 12 (day 84): pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose.	12 weeks
Pharmacokinetic of Aliskiren: The Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau(AUCtau)	Blood samples (2 mL) for the determination of aliskiren concentration in plasma were collected using an indwelling cannula inserted in a forearm vein. Samples were collected at week 12 (day 84): pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose.	12 weeks
Pharmacokinetic of Aliskiren: The Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)	Blood samples (2 mL) for the determination of aliskiren concentration in plasma were collected using an indwelling cannula inserted in a forearm vein. Samples were collected at week 12 (day 84): pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose.	12 weeks
Pharmacokinetic of Aliskiren: The Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)	Blood samples (2 mL) for the determination of aliskiren concentration in plasma were collected using an indwelling cannula inserted in a forearm vein. Samples were collected at week 12 (day 84): pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose.	12 weeks
Pharmacokinetic of Aliskiren: The Terminal Elimination Half-life (T½)	Blood samples (2 mL) for the determination of aliskiren concentration in plasma were collected using an indwelling cannula inserted in a forearm vein. Samples were collected at week 12 (day 84): pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose.	12 weeks

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Publications and helpful links

General Publications

• Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.

Study record dates

Study Major Dates

• Study Start: May 1, 2009
• Primary Completion (ACTUAL): February 1, 2011
• Study Completion (ACTUAL): February 1, 2011

Study Registration Dates

• First Submitted: June 17, 2009
• First Submitted That Met QC Criteria: June 17, 2009
• First Posted (ESTIMATE): June 18, 2009

Study Record Updates

• Last Update Posted (ESTIMATE): July 26, 2012
• Last Update Submitted That Met QC Criteria: July 19, 2012
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Keywords: Heart failure; PK; Pharmacokinetic; Aliskiren; PRA; BNP; Systolic; Angiotensin II; Ramipril; brain natriuretic peptide; Ang II; Plasma Renin Activity; Plasma Renin Concentration; PR,; urinary aldosterone; Escape
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Murmurs; Heart Failure; Systolic Murmurs; Heart Failure, Systolic; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Enzyme Inhibitors; Protease Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Ramipril
• Other Study ID Numbers: CSPP100A2252; EudraCT 2008-001035-35